Antagonism of amignoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients

Mitch Dowsett; Richard Murray; Paula Pitt; S.L. Jeffcoate

doi:10.1016/0277-5379(85)90292-5

Antagonism of amignoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients

Mitch Dowsett, Richard Murray, Paula Pitt, S.L. Jeffcoate

In: European Journal of Cancer and Clinical Oncology · 1985 · vol. 21(9) , pp. 1063–1068 · doi:10.1016/0277-5379(85)90292-5 · PMID:4065179 · W2053378295

article OA: closed CC0 ⤵ 1 in-corpus citation

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated the effectiveness of amignoglutethimide and danazol in suppressing serum free estradiol levels in breast cancer patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (1)

Danazol 2022

References (26)

Danazol treatment for advanced breast cancer via openalex
Endocrine effects of danazol in the treatment of endometriosis via openalex
Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer via openalex
TREATMENT OF DISSEMINATED BREAST CANCER WITH TAMOXIFEN, AMINOGLUTETHIMIDE, HYDROCORTISONE, AND DANAZOL, USED IN COMBINATION OR SEQUENTIALLY via openalex
doi:10.1210/jcem-27-9-1239 via openalex
doi:10.1136/bmj.286.6378.1615 via openalex
doi:10.1038/bjc.1983.100 via openalex
doi:10.1016/0305-7372(84)90033-1 via openalex
doi:10.1038/bjc.1984.183 via openalex
doi:10.1111/j.1365-2265.1974.tb03298.x via openalex
doi:10.1016/0277-5379(83)90112-8 via openalex
W2111903596 via openalex
W6643992471 via openalex
W6659055160 via openalex
W6676745997 via openalex
doi:10.1016/b978-0-12-571138-8.50016-0 via openalex
doi:10.1210/edrv-2-1-103 via openalex
doi:10.1111/j.1365-2265.1985.tb01083.x via openalex
doi:10.1016/0022-4731(77)90196-0 via openalex
doi:10.1016/s0140-6736(84)90596-8 via openalex
doi:10.1016/0022-4731(84)90290-5 via openalex
doi:10.1016/0002-9378(81)90611-6 via openalex
doi:10.1210/jcem-47-6-1257 via openalex
doi:10.1016/s0021-9258(19)70742-x via openalex
doi:10.1002/ijc.2910290105 via openalex
doi:10.1038/bjc.1983.232 via openalex

Cited by (1)

Danazol 2022

Source provenance

openalex: last seen: 2026-05-10T11:07:49.120799+00:00

License: CC0 · commercial use OK

[1] Endocrine effects of danazol in the treatment of endometriosis 1984

[2] Danazol treatment for advanced breast cancer 1983

[3] Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer 1982

[4] TREATMENT OF DISSEMINATED BREAST CANCER WITH TAMOXIFEN, AMINOGLUTETHIMIDE, HYDROCORTISONE, AND DANAZOL, USED IN COMBINATION OR SEQUENTIALLY 1984